Global Bowen Disease Treatment Market, by Drug Type (Fluorouracil, Imiquimod, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 356.5 million in 2021 and is expected to exhibit a CAGR of 4.5% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
Key players operating in the market are focusing on launching new drugs for the treatment of Bowen disease and this is expected to drive the market growth over the forecast period.
For instance, in August 2018, Oceanside Pharmaceuticals, Inc., a U.S. based pharmaceutical company, announced the launch of its generic version of Zyclara (imiquimod), which is manufactured by Bausch Health Companies Inc., a Canada based pharmaceutical company.
Global Bowen Disease Treatment Market – Impact of Coronavirus (Covid-19) Pandemic
COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 252 million cases and 5.1 million deaths due to Coronavirus (COVID-19) were reported up till November 14, 2021, across the globe.
The COVID-19 pandemic has negatively affected several markets across the globe and is also expected to hamper the demand and supply in global Bowen disease market, owing to lockdowns, halt of clinical trials related to cancer and lack of labour involved in manufacturing of drugs. For instance, according to an article published by the Nepal Journal of Epidemiology in September 2020, COVID-19 pandemic has raised various challenges in the field of clinical research such as implementation of strict guidelines which restrict physical interaction between the participants of a clinical trial study and the clinical trial personnel, thus leading to halt of clinical trials during the COVID-19 pandemic.
Browse 36 Market Data Tables and 30 Figures spread through 152 Pages and in-depth TOC on “Bowen Disease Treatment Market”- Global Forecast to 2028, by Drug Type (Fluorouracil, Imiquimod, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),
To know the latest trends and insights prevalent in the global Bowen disease treatment market, click the link below:
https://www.coherentmarketinsights.com/market-insight/bowen-disease-treatment-market-4791
Key players operating in the market are focusing on adoption of inorganic growth strategies such as collaborations, acquisitions, and others in order to strengthen their position in the global Bowen disease treatment market. For instance, in July 2018, Mayne Pharma Group Limited, an Australia based pharmaceutical company, acquired generic Efudex (fluorouracil cream 5%) from Spear Pharmaceuticals, Inc., a U.S. based pharmaceutical company.
Key Takeaways of the Global Bowen Disease Treatment Market:
- The global Bowen disease treatment market is expected to exhibit a CAGR of 4.5% over the forecast period, owing to high incidence of squamous cell carcinoma (Bowen disease). For instance, according to data provided by the American Society of Clinical Oncology (ASCO), as of February 2021, it is estimated that around 5.4 million cases of basal cell carcinoma and squamous cell carcinoma are diagnosed in the U.S., annually.
- Among drug type, fluorouracil is expected to account for largest market share in 2021, owing to clinical evidence of high efficacy of fluorouracil in the treatment of squamous cell carcinoma (including Bowen disease). For instance, according to an article published by the Journal of Drugs in Dermatology in November 2018, intralesional administration of 5-fluorouracil can be used successfully in the treatment of lower leg squamous cell carcinoma and other types of non-melanoma skin cancers such as Bowen disease.
- Key players operating in the global Bowen disease treatment market include Galderma S.A., Sirnaomics, Inc., PEPLIN INC, Ponce Therapeutics, Intas Laboratories Pvt Ltd, Cadila, Pharmaceuticals Ltd., VHB Life Sciences Limited, Neon Laboratories Ltd, Teva Pharmaceutical Ltd, and Actavis Group
